Quinapril and Hydrochlorothiazide 20/25
1 NDC across 1 manufacturer|1 Generic,0 Brand
▸ More about this market▾ Less
Quinapril and Hydrochlorothiazide 20/25 is available as 1 NDC from 1 manufacturer (1 generic, 0 brand), with NADAC prices from $0.48 to $0.48 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
1G / 0B
Manufacturers
1
competing in market
Price Spread
$0.48 – $0.48
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Cipla USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Angiotensin Converting Enzyme Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing QUINAPRIL AND HYDROCHLOROTHIAZIDE 20/25
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
QUINAPRIL-HYDROCHLOROTHIAZIDE 20-25 MG TAB | $0.4833 per EA | — |
Frequently Asked Questions
How many Quinapril and Hydrochlorothiazide 20/25 products are on the market?
The Quinapril and Hydrochlorothiazide 20/25 drug market contains 1 NDC from 1 manufacturer — 1 generic and 0 brand products.
What is the price range for Quinapril and Hydrochlorothiazide 20/25?
NADAC reference prices for Quinapril and Hydrochlorothiazide 20/25 range from $0.4833 to $0.4833 per EA.
Which manufacturers make Quinapril and Hydrochlorothiazide 20/25?
1 manufacturer lists Quinapril and Hydrochlorothiazide 20/25 in NADAC. Ranked by number of NDCs, the largest are Cipla USA Inc. (1).